Literature DB >> 16313187

The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation.

Kian Kani1, Euisun Park, Ralf Landgraf.   

Abstract

The extracellular, ligand binding regions of ErbB receptors consist of four domains that can assume at least two alternative conformations, extended and locked. The locked conformation, observed in several crystal structures, is held together by a noncovalent intramolecular tether and is incompatible with current models for receptor dimerization and ligand activation. Based on structures of ligand-receptor complexes in the extended conformation, the high affinity ligand binding pocket between domains I and III is disrupted in the locked conformation. Therefore the biological role of the locked conformation is not clear. To address the impact of the locked conformation on ligand binding, we compared extracellular domains of wild-type ErbB3, mutant domains in a constitutively locked or extended conformation and partial extracellular domain constructs. We found that the constitutively locked receptor domains and truncated constructs carrying only domains I-II or III-IV strongly bind ligand, albeit with reduced affinity compared to wild-type receptor. This suggests that the locked conformation cannot be discounted for ligand binding. The significant binding by both partial interfaces in domains I and III also suggests that "partial bivalency" may be the reason for the low nanomolar and high picomolar binding observed for ErbB3 in the respective "low" and high affinity states. In contrast to EGFR (ErbB1), ErbB3 retains high ligand binding affinity at an endosome-comparable pH in both the extended and locked conformations. Ligand affinity for the locked conformation even improves at low pH. For ErbB3, the contribution of domain I to ligand binding is strong and increases at low pH while its contribution is thought to be minimal for EGFR, regardless of pH. This shift in domain contribution and pH dependency provides a mechanistic explanation for some of the divergent properties of EGFR and ErbB3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313187     DOI: 10.1021/bi0515220

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Authors:  Maitreyee K Jathal; Liqun Chen; Maria Mudryj; Paramita M Ghosh
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-06

Review 2.  Insulin and epidermal growth factor receptor family members share parallel activation mechanisms.

Authors:  Kathryn M Ferguson; Chun Hu; Mark A Lemmon
Journal:  Protein Sci       Date:  2020-04-28       Impact factor: 6.725

3.  Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.

Authors:  Natalia Jura; Yibing Shan; Xiaoxian Cao; David E Shaw; John Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

4.  Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.

Authors:  Pei Jin; Juan Zhang; Malgorzata Beryt; Lisa Turin; Cathleen Brdlik; Ying Feng; Xiaomei Bai; Jim Liu; Brett Jorgensen; H Michael Shepard
Journal:  Mol Med       Date:  2008-11-17       Impact factor: 6.354

Review 5.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

6.  Higher-order association states of cellular ERBB3 probed with photo-cross-linkable aptamers.

Authors:  Euisun Park; Rose Baron; Ralf Landgraf
Journal:  Biochemistry       Date:  2008-10-23       Impact factor: 3.162

7.  An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

Authors:  Andrew P Garner; Carl U Bialucha; Elizabeth R Sprague; Joan T Garrett; Qing Sheng; Sharon Li; Olga Sineshchekova; Parmita Saxena; Cammie R Sutton; Dongshu Chen; Yan Chen; Huiqin Wang; Jinsheng Liang; Rita Das; Rebecca Mosher; Jian Gu; Alan Huang; Nicole Haubst; Carolin Zehetmeier; Manuela Haberl; Winfried Elis; Christian Kunz; Analeah B Heidt; Kara Herlihy; Joshua Murtie; Alwin Schuller; Carlos L Arteaga; William R Sellers; Seth A Ettenberg
Journal:  Cancer Res       Date:  2013-08-08       Impact factor: 12.701

Review 8.  HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.

Authors:  Ralf Landgraf
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

Review 9.  Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer.

Authors:  Kirstine Roepstorff; Lene Grøvdal; Michael Grandal; Mads Lerdrup; Bo van Deurs
Journal:  Histochem Cell Biol       Date:  2008-02-21       Impact factor: 4.304

10.  Recruitment of the adaptor protein Grb2 to EGFR tetramers.

Authors:  Noga Kozer; Dipak Barua; Christine Henderson; Edouard C Nice; Antony W Burgess; William S Hlavacek; Andrew H A Clayton
Journal:  Biochemistry       Date:  2014-04-21       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.